EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers

Mingjian Piao, Jiayu Xiao, Nan Zhang, Chengjie Li, Jiongyuan Li, Lihua Guan, Shuofeng Li, Zhe Zhu, Shi Feng, Boyu Sun, Dandan Li, Xuzhen Qin und 2 weitere

Translational Research · 2026

DOI: 10.1016/j.trsl.2026.01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2026. Verfasst von Mingjian Piao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Liver Neoplasms, Programmed Cell Death 1 Receptor, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Beijing Natural Science Foundation, Chinese Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown efficacy in hepatobiliary malignancies; however, reliable biomarkers for predicting treatment response remain limited. Peripheral PD-1⁺ T cells, which reflect both T-cell exhaustion and reinvigoration, may serve as novel immune correlates of clinical benefit. METHODS: We prospectively enrolled 99 patients with advanced hepatocellular carcinoma (HCC) or biliary tract cancer (BTC) who received ICIs at Peking Union Medical College Hospital between December 2023 and December 2024. Peripheral blood was collected at baseline and during treatment for flow cytometric quantification of PD-1⁺ T-cell subsets. Patients were randomly divided into a training cohort (n=69) and a validation cohort (n=30). Survival outcomes were analyzed using the Kaplan-Meier method. Baseline predictors were identified by least absolute shrinkage and selection operator (LASSO) regression, followed by nomogram construction. RESULTS: Responders exhibited significantly longer progression-free survival (PFS; 16.4 vs. 3.5 months, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsLiver NeoplasmsProgrammed Cell Death 1 ReceptorImmunotherapyCarcinoma, HepatocellularT-LymphocytesHumansFemaleMaleMiddle AgedAgedTreatment OutcomeProspective StudiesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Biliary tract cancer (BTC)Dynamic immune monitoringHepatocellular carcinoma (HCC)Immune checkpoint inhibitorsImmunotherapy response predictionPeripheral blood biomarkers

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Liver Surgery State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Laboratory Medicine State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College (CAMS & PUMC), Beijin…
  • Department of Liver Surgery State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic…

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • Beijing Natural Science Foundation
  • Chinese Society of Clinical Oncology

Zitieren

APA

Piao, M., Xiao, J., Zhang, N., Li, C., Li, J., Guan, L., Li, S., Zhu, Z., Feng, S., Sun, B., Li, D., Qin, X., Qiu, L., & Zhao, H. (2026). Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers. Translational Research. https://doi.org/10.1016/j.trsl.2026.01.004

Vancouver

Piao M, Xiao J, Zhang N, Li C, Li J, Guan L, et al. Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers. Translational Research. 2026. doi:10.1016/j.trsl.2026.01.004

BibTeX
@article{Piao2026,
  author = {Piao, Mingjian and Xiao, Jiayu and Zhang, Nan and Li, Chengjie and Li, Jiongyuan and Guan, Lihua and Li, Shuofeng and Zhu, Zhe and Feng, Shi and Sun, Boyu and Li, Dandan and Qin, Xuzhen and Qiu, Ling and Zhao, Haitao},
  title = {Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers},
  journal = {Translational Research},
  year = {2026},
  doi = {10.1016/j.trsl.2026.01.004}
}
Kostenlos starten →